Institutional Fund
Paradigm Biocapital Advisors LP
New York, NYCIK 18556555 filings on record
Portfolio Value
$4.89B
Q1 2026
Holdings
35
Reported positions
New Buys
10
Opened this quarter
QoQ Change
+31.0%
from $3.73B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Arcellx Inc13.5%
- Revolution Medicines Inc13.2%
- Nuvalent Inc11.1%
- Vaxcyte Inc5.7%
- Edgewise Therapeutics Inc4.7%
- Genmab A/S4.4%
- Other47.3%
Portfolio Holdings
35 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Arcellx Inc | 5.77M | $662.97M | 13.5% | +50.0K | Added |
| 2 | Revolution Medicines Inc | 6.66M | $647.27M | 13.2% | +11.3K | Added |
| 3 | Nuvalent Inc | 5.32M | $545.49M | 11.1% | +55.0K | Added |
| 4 | Vaxcyte Inc | 4.79M | $278.52M | 5.7% | +725.0K | Added |
| 5 | Edgewise Therapeutics Inc | 7.37M | $232.00M | 4.7% | +823.8K | Added |
| 6 | Genmab A/S | 7.97M | $213.78M | 4.4% | +928.0K | Added |
| 7 | Insmed Inc | 1.25M | $205.13M | 4.2% | +1.25M | New |
| 8 | Tarsus Pharmaceuticals Inc | 2.56M | $179.74M | 3.7% | 0 | Held |
| 9 | Belite Bio Inc | 1.11M | $177.74M | 3.6% | +1.11M | New |
| 10 | Erasca Inc | 10.39M | $168.15M | 3.4% | −3.77M | Reduced |
25 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio